Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II)

Journal of Psychiatric Practice

Volumn 10, Issue 3, 2004, Pages 177-181

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOGENIC AMINE; CALCIUM CHANNEL BLOCKING AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; LITHIUM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OPIATE AGONIST; PARACETAMOL; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

DISEASE EXACERBATION; DRUG ALCOHOL INTERACTION; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INDICATION; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; DYSKINESIA; HUMAN; HYPERACTIVITY; HYPERKINESIA; MENTAL DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRESCRIPTION; PSYCHOSIS; REVIEW; SEROTONIN SYNDROME; TREATMENT INDICATION;

DRUG INTERACTIONS; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2442640236     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200405000-00006     Document Type: Review

References (14)

1. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. Journal of Psychiatric Practice 2003;9:376-84.
2. Preskorn SH. The polypharmacology section. Series of columns on polypharmacology published in the Journal of Psychiatric Practice (www.preskorn.com/column1.html).
3. Preskorn SH. The overlap of DSM-IV sydromes: Potential implications for the practice of polypsychopharmacology, psychiatric drug development, and the human genome project. Journal of Psychiatric Practice 2002;8:170-7.
4. Preskorn SH. The stages of drug development and the human genome project: Drug discovery. Journal of Psychiatric Practice 2000;6:341-4.
5. Preskorn SH. The rationale for and clinical implications of dose-response curves. Series of columns published in the Journal of Psychiatric Practice (www.preskorn.com/column3.html).
6. Hardman JG, Limbird LE, Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York; McGraw Hill; 2001.
7. Thomson PDR. Physicians' desk reference, 58th edition. Montvale, NJ: Thomson PDR; 2004.
8. Preskorn SH. Defining "is." Journal of Practical Psychiatry and Behavioral Health 1999;5:224-8.
9. Preskorn SH. De-spinning in vitro data. Journal of Practical Psychiatry and Behavioral Health 1999;5:283-7.
10. Preskorn SH. Marooned: Only one choice. Journal of Practical Psychiatry and Behavioral Health 1998;4:110-4.
11. Preskorn SH. What happened to Tommy? Journal of Practical Psychiatry and Behavioral Health 1998;4:363-7.
12. Preskorn SH. The human genome project and modern drug development in psychiatry. Journal of Psychiatric Practice 2000;6:272-6.
13. Preskorn SH. Understanding the basics of antidepressant pharmacology. Series of columns published in the Journal of Psychiatric Practice (www.preskorn.com/column2.html).
14. Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle. Journal of Psychiatric Practice 2001;7:209-13.